Hypothyroidism Market share,Analysis, Outlook by Trends, Opportunities and Forecast to 2030
Hypothyroidism Market Overview
The Global Hypothyroidism
Market Share is expected to grow at a CAGR of 4.6% during the forecast period.
Increasing prevalence of hypothyroidism, advancements in healthcare facilities,
and favorable reimbursement and funding policies are expected to drive the
market growth over the forecast period. According to information suggested by
the 2022 guideline of the American Thyroid Association (ATA), 20 million
Americans had some form of hypothyroidism disorder. However, side-effects
related to available therapeutics can restrain the market growth over the
assessment period.
Hypothyroidism Market Segmentation
treatment, route of administration and end user.The market, on the
basis of type of hypothyroidism, has been segmented into primary
hypothyroidism, secondary hypothyroidism, and tertiary hypothyroidism.The
Global Hypothyroidism market Outlook, on the basis of diagnosis &
treatment, has been segmented into diagnosis and treatment. The diagnosis
segment is further classified as physical examination, blood tests, imaging
scan, and others. The treatment segment is further classified as levothyroxine
sodium, liothyronine, and natural desiccated thyroid (NDT).
The levothyroxine sodium is expected to hold the largest market
share owing to the growing prevalence of thyroid disorder, and effectiveness of
drug. The Synthroid drug by Abbvie holds the major share in the US market. In
2016, Abbvie Inc. generated revenue of 763 USD million with Synthroid drug in
US only.The Global Hypothyroidism
Market Trends, by route of administration, has been segmented into oral,
intravenous, and others. The Global market, on the basis of end users, has been
segmented into hospitals, clinics, research & academic institutes and
others.
Hypothyroidism Market Regional Analysis
prevalence of hypothyroidism. According to the American Thyroid
Association, more than 12% of the US population develops a thyroid disorder
during their lifetime. Europe is expected to hold the second largest position
in the global market owing to the favorable reimbursement and funding policies.
According to the Thyroid UK in 2016/2022, the National Health Service (NHS),
England spent more than ~USD 42 Million on liothyronine (a drug for the
treatment of hypothyroidism). Asia-Pacific is expected to be the fastest
growing market owing to the presence of a large patient pool and improving
healthcare infrastructure. According to a study published in the Journal of
Clinical and Diagnostic Research in 2016, nearly 42 Million people residing in
the country suffer from thyroid disorders. This prevalence of thyroid,
consequently, results in an increased demand for therapeutic. This is projected
to drive market growth. Moreover, the Middle East and Africa region is expected
to account for the least market share in the global market.
Key Players:
global
hypothyroidism market Players are Pfizer Inc., AbbVie Inc., Merck & Co.,
Inc., ALLERGAN, Mylan N.V., Erfa Canada Inc, Novartis AG, GlaxoSmithKline plc,
RLC Labs and others
At Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
.jpg)
Comments
Post a Comment